• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 5. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002

Recent Advances in the Study of 2-(7-Methyl-1H-benzimidazol-2-yl)ethanaminehydrochloride (CAS: 1713160-66-7)

2-(7-Methyl-1H-benzimidazol-2-yl)ethanaminehydrochloride (CAS: 1713160-66-7) is a benzimidazole derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This compound, characterized by its unique structural features, has been the subject of numerous studies aimed at exploring its pharmacological properties, synthesis methods, and therapeutic potential. The following research brief provides an overview of the latest findings related to this compound, highlighting key advancements and their implications for the field.

Recent studies have focused on the synthesis and optimization of 2-(7-Methyl-1H-benzimidazol-2-yl)ethanaminehydrochloride, with researchers employing various synthetic routes to improve yield and purity. One notable approach involves the use of microwave-assisted synthesis, which has been shown to significantly reduce reaction times while maintaining high product quality. Additionally, advancements in chromatographic purification techniques have enabled the isolation of the compound with greater efficiency, paving the way for its use in high-throughput screening and preclinical studies.

The pharmacological profile of 2-(7-Methyl-1H-benzimidazol-2-yl)ethanaminehydrochloride has also been a focal point of recent research. Preliminary in vitro and in vivo studies suggest that the compound exhibits promising activity against a range of biological targets, including enzymes and receptors implicated in inflammatory and neoplastic diseases. For instance, it has demonstrated inhibitory effects on certain kinases involved in cell proliferation, making it a potential candidate for anticancer therapy. Further investigations are underway to elucidate its mechanism of action and optimize its pharmacokinetic properties.

In addition to its therapeutic potential, the compound has been explored for its role as a building block in the design of novel drug candidates. Its benzimidazole core offers a versatile scaffold for chemical modifications, enabling the development of derivatives with enhanced bioactivity and selectivity. Recent publications have highlighted the synthesis of such derivatives and their evaluation in various disease models, underscoring the compound's utility in drug discovery pipelines.

Despite these advancements, challenges remain in the development of 2-(7-Methyl-1H-benzimidazol-2-yl)ethanaminehydrochloride as a viable therapeutic agent. Issues such as solubility, bioavailability, and potential off-target effects need to be addressed through further research. Collaborative efforts between academia and industry are essential to overcome these hurdles and translate the compound's potential into clinical applications.

In conclusion, 2-(7-Methyl-1H-benzimidazol-2-yl)ethanaminehydrochloride (CAS: 1713160-66-7) represents a promising area of research in the field of medicinal chemistry. Its unique structural and pharmacological properties make it a valuable candidate for further investigation, with the potential to contribute to the development of new therapeutic agents. Continued research and innovation will be crucial in unlocking its full potential and addressing the challenges associated with its development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)